Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

 
• By Alaric DeArment
Schizophrenia
Sumitomo and Otsuka have entered a deal of up to $890m centered on psychiatric drugs • Source: Shutterstock

More from Deals

More from Business